REGN

746.58

0.10% -0.78

Dopo l'orario di chiusura: 745.79 -0.79 -0.11%

Regeneron Pharmaceuticals Inc (REGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché REGN Giù? Forum Previsione

Precedente Chiudi:

$747.36

Aprire:

$751.48

Volume 24 ore:

901.79K

Relative Volume:

1.28

Capitalizzazione di mercato:

$78.93B

Reddito:

$14.34B

Utile/perdita netta:

$4.50B

Rapporto P/E:

17.96

EPS:

41.5626

Flusso di cassa netto:

$3.77B

1 W Prestazione:

-0.97%

1M Prestazione:

+1.87%

6M Prestazione:

+27.68%

1 anno Prestazione:

+27.51%

Intervallo 1D:

$740.47

$755.78

Intervallo di 1 settimana:

$734.12

$758.61

Portata 52W:

$476.49

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare (1109)

Industria

Biotechnology (620)

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Dipendente

15,410

Cinguettio

@regeneron

Prossima data di guadagno

2026-04-29

Ultimi documenti SEC

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REGN Regeneron Pharmaceuticals Inc	746.58	79.01B	14.34B	4.50B	3.77B	41.56
VRTX Vertex Pharmaceuticals Inc	437.67	111.05B	12.07B	3.95B	3.19B	15.33
ARGX Argen X Se Adr	793.22	50.08B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	310.58	41.15B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.41	34.67B	5.36B	287.73M	924.18M	2.5229

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-31	Ripresa	Piper Sandler	Overweight
2026-03-06	Iniziato	Barclays	Overweight
2026-01-07	Aggiornamento	BofA Securities	Underperform → Buy
2025-12-03	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Iniziato	HSBC Securities	Buy
2025-11-24	Ripresa	Truist	Buy
2025-11-13	Iniziato	Scotiabank	Sector Perform
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Ripresa	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Overweight
2021-12-07	Ripresa	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Ripresa	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Ripresa	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Apr 22, 2026

FDA approves dupilumab for chronic spontaneous urticaria in children 2 years and older - Contemporary Pediatrics

Apr 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria - The Manila Times

Apr 22, 2026

First biologic for kids as young as 2 wins U.S. approval for chronic hives - Stock Titan

Apr 22, 2026

Raymond James reiterates Outperform on Regeneron stock at $910 target By Investing.com - Investing.com Canada

Apr 22, 2026

Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran - Citeline News & Insights

Apr 22, 2026

Fund Update: 25,606 REGENERON PHARMACEUTICALS (REGN) shares added to WestEnd Advisors, LLC portfolio - Quiver Quantitative

Apr 22, 2026

REGN: Flexible C5 inhibition strategy shows strong efficacy in PNH and gMG, with major catalysts ahead - TradingView

Apr 22, 2026

Regeneron (REGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 22, 2026

TD Waterhouse Canada Inc. Has $5.29 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 22, 2026

REGN: Cemdisiran ± pozelimab shows late-stage efficacy and commercial promise in gMG, PNH, and GA - TradingView

Apr 22, 2026

Regeneron Pharmaceuticals (REGN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 22, 2026

Non-Proliferative Diabetic Retinopathy Market to Reach USD - openPR.com

Apr 22, 2026

Apr 21, 2026

Regeneron’s Lunsekimig Data Expand Immunology Story Beyond Dupixent Dependency - simplywall.st

Apr 21, 2026

Regeneron (REGN) Presents NIMBLE Trial Findings for Cemdisiran i - GuruFocus

Apr 21, 2026

Regeneron Pharmaceuticals Announces Positive Phase 3 NIMBLE Trial Results For Cemdisiran In gMG - TradingView

Apr 21, 2026

Regeneron announces publication of Phase 3 NIMBLE trial results - TipRanks

Apr 21, 2026

Regeneron submits U.S. application for gMG treatment cemdisiran By Investing.com - Investing.com Canada

Apr 21, 2026

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial - The Manila Times

Apr 21, 2026

A shot every 12 weeks controlled myasthenia gravis in Phase 3 - Stock Titan

Apr 21, 2026

Zurcher Kantonalbank Zurich Cantonalbank Sells 17,601 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 21, 2026

Private Wealth Partners LLC Purchases Shares of 2,270 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Apr 21, 2026

Graves' Ophthalmopathy Treatment Market to Reach USD 3.01 - openPR.com

Apr 21, 2026